Notizie

For the quarter ended March 2024, Bristol Myers Squibb (BMY) reported revenue of $11.87 billion, up 4.7% over the same period last year. EPS came in at -$4.40, compared to $2.05 in the year-ago quarter.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Recent LOE Products- Abraxane- U.S. $145 million compared to the $168.38 million average estimate based on four analysts. The reported number represents a change of -10.5% year over year.
• Net Sales- In-Line Products- Opdivo- U.S. $1.16 billion versus the four-analyst average estimate of $1.33 billion. The reported number represents a year-over-year change of -10.5%.
• Net Sales- In-Line Products- Pomalyst/Imnovid- U.S. $597 million versus the four-analyst average estimate of $570.48 million. The reported number represents a year-over-year change of +9.5%.
• Net Sales- In-Line Products- Pomalyst/Imnovid- International: $268 million versus $245.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.
• Net Sales- New Product Portfolio- Sotyktu: $44 million compared to the $50.23 million average estimate based on five analysts. The reported number represents a change of +175% year over year.
• Net Sales- In-Line Products- Yervoy: $583 million versus $551.90 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +14.8% change.
• Net Sales- New Product Portfolio- Abecma: $82 million versus the five-analyst average estimate of $100 million. The reported number represents a year-over-year change of -44.2%.
• Net Sales- New Product Portfolio- Breyanzi: $107 million versus the five-analyst average estimate of $111.63 million. The reported number represents a year-over-year change of +50.7%.
• Net Sales- New Product Portfolio- Camzyos: $84 million versus $104.67 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +189.7% change.
• Net Sales- New Product Portfolio- Reblozyl: $354 million compared to the $324.90 million average estimate based on five analysts. The reported number represents a change of +71.8% year over year.
• Net Sales- New Product Portfolio- Zeposia: $110 million versus $121.45 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +41% change.
• Net Sales- Recent LOE Products- Revlimid: $1.67 billion compared to the $1.23 billion average estimate based on five analysts. The reported number represents a change of -4.6% year over year.

View all Key Company Metrics for Bristol Myers here>>>

Shares of Bristol Myers have returned -8.2% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

(We are reissuing this article to correct a mistake. The original article, issued earlier today, should no longer be relied upon.)

Free – 5 Dividend Stocks to Fund Your Retirement

Zacks Investment Research has released a Special Report to help you prepare for retirement with 5 diverse stocks that pay whopping dividends. They cut across property management, upscale outlets, financial institutions, and a couple of strong energy producers.

5 Dividend Stocks to Include in Your Retirement Strategy is packed with unconventional wisdom and insights you won’t get from your neighborhood financial planner.

Download Now – Today It’s FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.